SecurityNGS / Natural Gas Services Group, Inc. (63886Q109)
IndustryOil and Gas Field Services, Not Elsewhere Classified
Common Shares Outstanding13,085,607 shares (as of 2018-03-31)
Total Insiders7
Total Directors5
Total Officers3

Stock Insider Trading (from SEC Form 4)

Natural Gas Services Group, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

NGS / Natural Gas Services Group, Inc. insiders include BRADSHAW DAVID L, and HUGHES WILLIAM F JR CURTIS CHARLES G, CHISHOLM JOHN, Hazlett James R, Lawrence G Larry, Taylor Stephen Charles, .

Insider Roster

Insider Dir Off 10% Shares Owned
Lawrence G Larry Chief Financial Officer
X 57,150
Hazlett James R VP -- Technical Services
X 63,034
HUGHES WILLIAM F JR Director
X 149,368
CHISHOLM JOHN Director
X 10,964
BRADSHAW DAVID L Director
X 19,572
Taylor Stephen Charles Chief Executive Officer, Director
X X 337,801
CURTIS CHARLES G Director
X 80,085

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-04-06 4 Hazlett James R F D 24.5 -2,735 63,034
2018-04-06 4 Lawrence G Larry F D 24.5 -2,711 57,150
2018-03-31 4 HUGHES WILLIAM F JR By Rabbi Trust M I 898 149,368
2018-03-28 4 CHISHOLM JOHN S D 23.2 -4,511 10,964 254,365
2018-03-27 4 CHISHOLM JOHN S D 24.07 -9,569 15,475 372,483
2018-03-26 4 CHISHOLM JOHN S D 24.13 -4,110 25,044 604,312
2018-03-23 4 CHISHOLM JOHN S D 24.35 -2,750 29,154 709,900
2018-03-23 4 Lawrence G Larry F D 23.9 -617 54,861
2018-03-23 4 Lawrence G Larry By Rabbi Trust M I 5,000 5,000
2018-03-23 4 Hazlett James R F D 23.9 -513 60,769
2018-03-23 4 Hazlett James R By Rabbi Trust M I 5,000 5,000
2018-03-15 4 HUGHES WILLIAM F JR A D 24.55 407 148,470
2018-03-15 4 CURTIS CHARLES G A D 24.55 4,072 80,085
2018-03-15 4 CHISHOLM JOHN A D 24.55 4,072 31,904
2018-03-15 4 Taylor Stephen Charles A D 24.55 56,749 337,801
2018-03-15 4 Lawrence G Larry A D 24.55 16,000 55,478
2018-03-15 4 Hazlett James R A D 24.55 16,000 61,282
2018-03-15 4 BRADSHAW DAVID L A D 24.55 4,072 19,572
2018-03-13 4 BRADSHAW DAVID L S D 27.35 -1,853 15,500 423,925
2018-03-13 4 BRADSHAW DAVID L S D 27.11 -647 17,353 470,440
2018-02-14 4 Taylor Stephen Charles F D 26.3 -1,278 259,913
2018-02-14 4 Taylor Stephen Charles By Rabbi Trust M I 21,139 21,139
2018-01-25 4 Hazlett James R S D 28.9 -102 45,282 1,308,650
2018-01-25 4 Hazlett James R M D 17.51 102 45,384
2018-01-24 4 Hazlett James R S D 28.9 -200 44,430 1,284,027
2018-01-24 4 Hazlett James R M D 17.51 200 44,630
2018-01-23 4 Hazlett James R S D 29 -513 44,430 1,288,470
2018-01-23 4 Hazlett James R S D 28.95 -979 44,943 1,301,100
2018-01-23 4 Hazlett James R M D 17.51 979 45,922
2018-01-22 4 Hazlett James R S D 28.9 -198 44,943 1,298,853
2018-01-22 4 Hazlett James R M D 17.51 198 45,141
2018-01-17 4 Hazlett James R S D 28.96 -2,005 44,943 1,301,549
2018-01-17 4 Hazlett James R S D 29.01 -1,688 46,948 1,361,961
2018-01-17 4 Hazlett James R M D 17.51 2,005 48,636
2018-01-16 4 Hazlett James R S D 29.02 -1,201 46,631 1,353,232
2018-01-16 4 Hazlett James R S D 28.95 -1,239 47,832 1,384,736
2018-01-16 4 Hazlett James R M D 17.51 1,239 49,071
2018-01-12 4 Hazlett James R S D 28.92 -277 47,832 1,383,301
2018-01-12 4 Hazlett James R M D 17.51 277 48,109
2018-01-06 4 Taylor Stephen Charles F D 27.4 -15,897 261,191
2017-12-27 4 CHISHOLM JOHN S D 26.05 -1,400 27,832 725,024
2017-12-27 4 CHISHOLM JOHN A D 20.48 2,500 29,232
2017-12-27 4 CHISHOLM JOHN S D 26.05 -2,500 26,732 696,369
2017-12-27 4 CHISHOLM JOHN A D 19.61 2,500 29,232
2017-12-21 4 CURTIS CHARLES G A D 20.48 2,500 76,013
2017-12-19 4 Taylor Stephen Charles S D 25.17 -16,212 277,088 6,974,305
2017-12-19 4 Taylor Stephen Charles A D 20.06 16,212 293,300
2017-12-19 4 Lawrence G Larry S D 25.23 -6,000 39,478 996,030
2017-12-11 4 CURTIS CHARLES G M D 19.61 2,500 73,513
2017-10-03 4 Taylor Stephen Charles S D 28.58 -3,874 277,088 7,919,175
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Natural Gas Services' (NGS) CEO Stephen Taylor on Q4 2017 Results - Earnings Call Transcript

2018-03-08 seekingalpha
Natural Gas Services Group, Inc. (NYSE:NGS) Q4 2017 Earnings Conference Call March 8, 2018 11:00 AM ET

BRIEF-Natural Gas Services Group Reports Q4 Adjusted Net Income Per Share $0.03

2018-03-08 reuters
* NATURAL GAS SERVICES GROUP - NET INCOME FOR 3 MONTHS ENDED DEC 31, 2017 INCREASED TO $18.7 MILLION VERSUS NET INCOME OF $1.2 MILLION FOR SAME PERIOD IN 2016